Healthcare Associated Infections (HAI)

Increased sales of these antibiotics during the COVID-19 pandemic raise concerns about the growing threat of antimicrobial resistance.

After 28 days, hydrocortisone reduced the risk of mortality by 5.7% in severe community-acquired pneumonia patients.

This study analyzed concerns that a lack of time may lead primary care physicians to prescribe unnecessarily as a “quick fix.”

The seasonal respiratory virus could be the challenging, lingering colds people are suffering with this year.

In the 12-month period following COVID-19 infection, long COVID patients had an excess death rate of 16.4 per 1000 individuals.

Periods of COVID-19 reinfection correlated with the circulation of new variants, as well as with time since first infection.

A single oral dose of azithromycin reduced the risk of maternal sepsis or death by 33% in women who delivered vaginally.

Antimicrobial stewardship programs can protect drugs listed on the WHO Watch List, but the benefits are also dependent on countries' income level.

Higher poverty, crowding, and lower education levels disproportionately increased a person’s risk of S aureus infection, according to a new study.

Bacterial co-infections with COVID-19 are uncommon, but frequent use of antibiotics has fostered treatment resistance in co-occurring and secondary infections.

Implementing rapid near patient testing (NPT) reduced patient isolation time, length of hospital stay, antibiotic usage, and overall cost.

If approved on its March PDUFA date, rezafungin could be the first new Candida treatment option in over a decade.

Sepsis is the number 1 cause of death in hospitals. The FDA approval of IntelliSep, the first sepsis diagnostic tool, could change this.

Fecal microbiota transplantation (FMT) is known to be an effective treatment for recurrent Clostridioides difficile infection. New research reveals why.

November is C difficile Awareness Month. We're recapping the most significant potential therapies and remaining challenges from the past month.

COVID-19 isolation wards should employ additional contact precautions and environmental cleaning alongside regular COVID-19 precautions, such as personal protective equipment, in order to prevent multidrug-resistant infections.

Antimicrobial stewardship works, one IDWeek 2022 study found.

Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.

Hospitalization rates increased significantly after sepsis, with 11.9% of survivors rehospitalized for recurrent sepsis, and 56.6% receiving outpatient anti-infective treatment.

People exposed to a family member recently hospitalized with C difficile infection were 73% more likely to contract CDI themselves.

SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.

Investigators performed a systematic review to assess just how strong the association between race and urinary tract infections (UTIs) in children.

About 65% of patients with metronidazole-resistant recurrent C difficile infection benefitted from taking rifaximin.

Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.

During the pandemic, antibiotic-resistant bacterial infections increased in hospitalized patients who tested positive or negative for COVID-19.

The greatest risk factors for recurrent Clostridioides difficile infection (CDI) were age of at least 65 years, severe primary CDI, and use of non-CDI antibiotics. Patients with these risk factors should be prioritized for bezlotoxumab therapy.

Selecting initial antibiotic for ventilator-associated pneumonia from Gram staining and resistance records could reduce broad spectrum agents.

A new report based on samples from Texas and Kenya found significant proportions of samples from patients with CDI had nonsusceptible isolates.

For the first time, a research team mapped C difficile’s outer “S-layer,” finding the dangerous bacteria’s chainmail-like shell enables it to be highly resistant.

To reduce antimicrobial resistant pathogens, nursing homes should carefully monitor their use of hospital-grade antibiotics.